middle.news
How Vitrafy’s $32.7M Loss Fuels Next-Gen Cryopreservation Breakthroughs
8:42am on Tuesday 5th of August, 2025 AEST
•
Healthcare
Read Story
How Vitrafy’s $32.7M Loss Fuels Next-Gen Cryopreservation Breakthroughs
8:42am on Tuesday 5th of August, 2025 AEST
Key Points
FY25 loss widens to $32.7 million from $10.4 million in prior year
Successful $35 million IPO completed in November 2024
Awarded $4.8 million Australian government grant to accelerate commercialization
Advancing VCU2 device and LifeChain software for human and animal health markets
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vitrafy Life Sciences (ASX:VFY)
OPEN ARTICLE